NCT00003339View on ClinicalTrials.gov

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 1998

Primary Completion Date

November 30, 1999

Study Completion Date

September 30, 2004

Conditions
Intraocular MelanomaMelanoma (Skin)
Interventions
BIOLOGICAL

gp100 antigen

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

recombinant interleukin-12

BIOLOGICAL

tyrosinase peptide

Trial Locations (2)

91010

Beckman Research Institute, City of Hope, Duarte

90033-0800

USC/Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER